Rekombinanter SARS-CoV-2 Spike (Sotrovimab Biosimilar) Antikörper

Produktnummer ABIN7795138

Der Human Monoklonal anti-SARS-CoV-2 Spike (Sotrovimab Biosimilar) Antikörper (ABIN7795138) detektiert spezifisch SARS-CoV-2 Spike (Sotrovimab Biosimilar) in FACS und in vivo. Dieser Antikörper reagiert spezifisch mit Proben aus Human.

Kurzübersicht für Rekombinanter SARS-CoV-2 Spike (Sotrovimab Biosimilar) Antikörper (ABIN7795138)

Target: SARS-CoV-2 Spike (Sotrovimab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Human

Klonalität: Monoklonal

Konjugat: Dieser SARS-CoV-2 Spike (Sotrovimab Biosimilar) Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), In vivo Studies (in vivo)

Güteklasse: Research Grade

Produktdetails anti-SARS-CoV-2 Spike (Sotrovimab Biosimilar) Antikörper

Expressionssystem: Mammalian cells

Verwendungszweck: Sotrovimab Biosimilar, SARS-CoV-2 Spike Monoclonal Antibody

Produktmerkmale: What is sotrovimab biosimilar research grade? Sotrovimab is an Fc-engineered human monoclonal antibody directed against the spike protein of SARS-CoV-2. sotrovimab is a human monoclonal antibody (IgG1κ isotype). sotrovimab biosimilar uses the same protein sequences as the therapeutic antibody sotrovimab. sotrovimab/imdevimab is a combination medicine used for the treatment and prevention of COVID-19. It consists of two human monoclonal antibodies, sotrovimab and imdevimab that must be mixed together and administered as an infusion or subcutaneous injection. The combination of two antibodies is intended to prevent mutational escape. sotrovimab and imdevimab bind distinct epitopes on the RBD with dissociation constants KD of 46 and 47 pM, respectively. Please contact us if you are interested in the anti-SARS-CoV-2 spike monoclonal antibody imdevimab biosimilar.

Aufreinigung: Protein A or G affinity column

Reinheit: >95 % by reducing SDS-PAGE

Endotoxin-Niveau: < 1 EU per 1 mg of the protein by the LAL method

Isotyp: IgG1, kappa

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: > 3 mg/mL

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Details zu SARS-CoV-2 Spike (Sotrovimab Biosimilar)

Target: SARS-CoV-2 Spike (Sotrovimab Biosimilar)

Andere Bezeichnung: Sotrovimab Biosimilar

Substanzklasse: Biosimilar